Try our Advanced Search for more refined results
Life Sciences - September, 2016
342 articles
- J&J Faces Hip MDL Trial Amid Series Of Pro-Plaintiff Rulings
- Depomed Gets Patent Win Over Generic Nucynta Drugmakers
- DOJ Says Execs' Convictions Unrelated To Free Speech
- Time Clocks Improve Patent Trials, Litigators Say
- Patent Trial Judges Oppose Posner's Push For Neutral Experts
- Ex-Pharma Co. CEO Indicted Over $100M Fraud Scheme
- Hospira Can't Escape Contract Claims In GSK Vaccine Suit
- Patients Blast Cook's Bellwether Pick In Vein Filter MDL
- Momenta, Sandoz Can't Beat Blood Clot Drug Monopoly Suit
- Walgreen Escapes Most Of Investor Suit Over Alliance Buy
- GlaxoSmithKline To Pay $20M SEC Fine Over China Bribery
- Del. Judge Denies Quick Wins In Device Co.'s Coverage Battle
- Par Sues FDA For Yanking Gout Drug's 180-Day Exclusivity
- Teva Knocks Out FCPA Probe Retaliation Suit
- Adare, Teva Say Apotex Infringed Patent With Amrix Generic
- Co.'s E. Coli, Salmonella Losses Aren't Covered, Underwriters Say
- Charitable Donations And FCPA Risks: Lessons From Nu Skin
- Fed. Circ. On-Sale Bar Case Could Make Axing Patents Harder
- Oral Advocacy And 'Vocal Fry'
- $200K Fee Request Questioned In Mooted Class Case
- Drug Cos. Lose Bid to Stay Chicago's Opioid Marketing Suit
- SEC, DOJ Accuse Ex-Drug Exec Of Insider Trading Scheme
- IRS Gets Win In $24M Fight With Abbott Exec's Estate
- LivaNova Escapes Suit Over Blood Temp Equipment
- Insurer Needn't Cover $5M HIPAA Probe Costs, 9th Circ. Told
- Express Scripts Gets $65M In Horizon Rebate Breach Deal
- Ex-Insys Manager Charged In Fentanyl Kickback Scheme
- Bankrupt Firm's Execs Can't Dodge Breach Of Duty Suit
- 3 Cos. Price IPOs Totaling $329M At Bottom Or Below Range
- Ohio Surgery Center Loses Bid To Escape FCA Spat
- Bristol-Myers Wants Abilify Gambling Suits Sent To Florida
- Grouping J&J Suits Poses Delays For Terminally Ill, JPML Told
- Real Estate Rumors: Madison, Pineapple Grove, Lonza
- Atty Dodges DQ, But Has Witness Statements Trashed
- 5 Tips For Preparing Sales Reps For Trial Examination
- 2nd Circ. Creates Confusion For FDA-Vetted Marketers
- Suit Over Weak IVF Drug Survives Dismissal Bid
- Benicar MDL Plaintiffs Can't Depose Foreign Witnesses
- Patients Urge Same Schedule For 3 Trials In Vein-Filter MDL
- Boehringer Can Hide Emails In FTC Pay-For-Delay Suit
- 'Unicorn' Nutanix Raises IPO Target Price
- Biopharm, Fee Cases Nixed In Del. Nod To Calif. Forum Pick
- Merck Stays Clear Of Ex-Worker's Sex Bias Claim
- Squire Draws Tokyo Arbitration, Life Sci Pro From K&L Gates
- Pharmacy Exec Wants Civil Docs In Meningitis Murder Trial
- Sens. Ask DOJ If Mylan's EpiPen Rebates Violate FCA
- The Courtroom Where It Happened: Hamilton As A Lawyer
- Congress Reaches Deal To Avoid Gov't Shutdown
- Mylan Antitrust Suit Over Acne Drug Rejected By 3rd Circ.
- 5th Circ. Upholds Video Testimony In J&J Hip MDL
- International Comity Saves Vitamin C Defendants
- Why Have Lawyers Forgotten About The Middle Class?
- Ethicon Says Rival's Suit An Attempt To Nix Poaching Claims
- Teva Alleges Fraud In $2B Purchase Of Mexican Drug Co.
- Pharma Co. Linked To Ex-Gov. McDonnell Scandal Hits Ch. 7
- And Now A Word From The Panel: 3 Alternatives To MDLs
- Pa. Appeals Court Urged To Junk Risperdal Time Bar
- Bayer Hits BASF With Suit Over Herbicide Patent
- FDA Warning Wire: Sketchy SuperValu Seafood, Tainted Drugs
- Medical Implant Co. Can't Secure Defamation Coverage
- Sales Rep Wants Docs Public In $40B Celgene FCA Row
- Drugmakers Tell 3rd Circ. To Punt Effexor To Fed. Circ.
- Deals Rumor Mill: Blue Apron, Dick Clark Productions, Bayer
- EcoMed Says Japanese Co. Breached $22M Distribution Pact
- Genetic Info Firm Nabs $45M From Bono, Private Investors
- Lipitor Buyers Ask 3rd Circ. To Keep Pay-For-Delay Fight
- The Role Of Value And Cost In Prescription Drug Pricing
- Advanced Disposal 1 Of 4 IPO Launches Totaling $745M
- 'Natural' Menopause Drug Deception Suit Survives Dismissal
- Anticipating And Avoiding Expert Deposition Fee Disputes
- House OKs Bill Broadening DEA Drug Targeting Powers
- Corn Producers Get Class Cert. In Syngenta GMO MDL
- Fed. Circ. Says Carnitine Classified As Duty-Free
- Full Fed. Circ. Won't Eye Ruling On New AIA Review Evidence
- Cephalon Faces Pa. Suit Over Opioid Marketing After Death
- Docs Treating Opioid Addicts To Report Details To HHS
- Amgen Sues Actavis, Indian Cos. Over Sensipar Generics
- Judge Orders Depositions Of Ex-Forest Labs Employees
- Pregnancy Test Maker Asks 2nd Circ. To Rehear False Ad Row
- Third Time's Not The Charm For Opioid Painkiller At FDA
- Rankled Avon Users Ask 2nd Circ. To Reverse Class Denial
- PhRMA Rips Feds For 'Regulation By Litigation' On Kickbacks
- Alere Hit With New Complaint Over $5.8B Abbott Merger
- Pfizer Again Ditches Plan to Split Into 2 Businesses
- Pa. Judge Urged To Consolidate Philly Invokana Cases
- Bid To Pause PharmaCare Herbal Sex Pill Suit Comes Up Short
- You Don't Need A Data Breach To Face Regulatory Scrutiny
- GSK Still Wants Hearing On Expert Of Reed Smith Atty's Widow
- Mylan Asks High Court To Rule On Venue For ANDA Cases
- 3 Firms Prime IPOs Totaling $547M Led By 'Unicorn' Nutanix
- High Court Asked To Nix PTAB Power To Start AIA Reviews
- 2nd Circ. Says CoreLogic Doesn't Have To Pay $4M In FTC Suit
- FDA Approves Amgen's Humira Biosimilar
- Health Hires: BakerHostetler, Hinckley Allen, Ballard Spahr
- Rainmaker Q&A: Hogan Lovells' Alice Valder Curran
- J&J Invokana Suits Should Be An MDL, Patients Say
- Generic EpiPen Will Likely Secure Profits For Mylan
- FCC Fines Siemens $175K For Hiding FCPA Felonies
- Drug Cos. Tell 3rd Circ. To Affirm Eye Drop Suit Dismissal
- Seniors Urge 9th Circ. To Revive Suit Over Muscle Drink
- 35 States Sue Indivior In Antitrust Row Over Suboxone
- Medtronic Avoids Off-Label Spinal Fusion Device Suit
- Costco Fights 9th Circ. Appeal Over Apotex Drug's Origins
- GSK Exec Can't Dodge Whistleblower's Firing Suit
- Bayer Willing To Give Up $1.6B Yearly To Land Monsanto
- Senate GOP Pushes Gov't Funding Band-Aid, As Dems Balk
- Fed. Circ. Affirms J&J Win In Roche Blood Test Patent Case
- White & Case Snags Ex-Ropes & Gray IP Partner
- Pharmacist In $150M Drug Fraud Gets Up To 6 Years In Prison
- FTC Asks To Keep Lifewatch Execs On Hook In Phone Scam
- Ohio Attys Now Safe To Advise On Legal Marijuana Activity
- Free Speech No Defense In Fatal Meningitis Outbreak: Judge
- Teva, Apotex, Mylan Sued Over 'Extreme' Statin Prices
- Allergan Seeks Full 3rd Circ. Look At Eye Drop Antitrust Suit
- Practical Uses For Machine Learning In Health Care Cases
- Ex-Hospital CEO Says Attys' Prostitution Claim Defamed Him
- GNC, Supplement Cos. Get ThermoLife Amino Patents Nixed
- Ex-Hearing Aid Co. Execs Indicted For Embezzling $20M
- Biz Groups Back Aventis In 10th Circ. Label-Warning Fight
- House Committee Frustrated At Mylan CEO's Tight Lip
- Chancery OKs $24M Settlement In Caris Stock Option Dispute
- Fresenius Scores Preliminary Injunction In Drug Patent Case
- Hospital Consultant Seeks Quick Win In FCA Retaliation Suit
- Anthem, Cigna Both Claim Merger Breach, DOJ Says
- Latham-Led Tech Startup, Biotech IPOs Raise $129M
- Mass. Court Upholds Dismissal Of J&J Birth Control Suit
- Otsuka Sues Indian Pharma Cos. Over Planned Abilify Generic
- Land O'Lakes To Appeal Tainted Whey Suit Dismissal
- Rainmaker Q&A: Wolf Greenfield's Jason Honeyman
- Dow Not Warning Calif. Residents Of Pesticide Use, Suit Says
- Nu Skin Settles With SEC In China Charity-Donation Probe
- Ill. Judge Trims Claim From J&J Baby Powder Class Action
- Girardi Keese Nears Escape From $4.4M GSK Fee-Split Fight
- AstraZeneca IP Suit Survives Generics Co.'s Application Swap
- Senate Starts Stopgap Funding Debate, Details In Flux
- FDA Warning Wire: A New Cop On The E-Cig Beat
- Abbott Scores Fed. Circ. Win In 20-Year Yeda Patent Battle
- Overhauling Law Firm Records Departments For A New Reality
- 2nd Circ. Vitamin C Ruling A Landmark For Comity
- W.Va. AG Says Mylan Dodged EpiPen Subpoena
- Taylor-Wharton Wins Liquidating Ch. 11 Plan Confirmation
- Ex-Akebia Manager Pleads Not Guilty To Insider Trading
- Drug Cos. Pledge To Tackle Antibiotic Overuse, Pollution
- Big Pharma Backs Acclarent Execs In Off-Label Case
- Rainmaker Q&A: Holland & Knight's Jeffrey Mittleman
- Shire Prices $12.1B Bond To Help Pay For Baxalta Deal
- The Potential For Litigation In New Era Of Biosimilars
- Deals Rumor Mill: Bayer, Naspers, Rabobank
- Allergan Grabs Liver Disease Drugmaker In Up-To-$1.7B Deal
- $147M Award In Vitamin Antitrust Suit Vacated By 2nd Circ.
- Sanofi Hits Merck With Patent Suit Over New Diabetes Drug
- After Searing Debate, FDA Clears Unproven Sarepta Drug
- Supplement Co. Can't Ditch Claim It Rigged Amazon Reviews
- Quinn Emanuel Agrees To Duck Out Of Elan Investor Suit
- Gov't Band-Aid Funding Debate Stalled By Senate
- Ex-Kaye Scholer Atty In Shkreli Fraud Case Wants More Info
- Herbicide In Monsanto's Roundup 'Unlikely' To Cause Cancer
- Deals Rumor Mill: Bayer, BRF, Saudi Telecom
- Enviros Ask FDA To Withdraw Livestock Antibiotic Approvals
- PharmaCare Says No To Stay In Herbal Sex Pill Suit
- NuScience Renews Bid To Have Brothers Jailed In IP Row
- Judge OKs $486M Celebrex, Bextra Securities MDL Deal
- 'Unicorn' Nutanix Among 4 IPO Launches Totaling $543M
- GSK Lowers Cost Of Pneumonia Vaccine For Child Refugees
- In Congress: A Continuing Resolution?
- Shire Loses Patent Suit Against Zydus Over Generic Lialda
- GSK, Teva Drug Caused Child's Cancer, Parents Tell 9th Circ.
- 8 Firms To Guide IPOs Surpassing $1.1B Led By Valvoline
- German Cryo-Chamber Maker Wants Arbitration In €4M Row
- Roche Seeks To Toss Accutane Ulcerative Colitis Testimony
- Tucker Ellis Adds Six Attorneys In Chicago
- Fed. Circ. Upholds LifeNet's $35M Win In Graft Patent Suit
- Deals Rumor Mill: WhisperText, Depomed, Techem
- Marijuana Legalization Votes Won't End Drug-Free Workplaces
- Taxation With Representation: Sullivan, Wachtell, Jones Day
- Medical Supplier Says Safe Harbor Applied In FCA Row
- FDA Accuses 2 Drug Cos. Of Marketing Unapproved Opioid
- SynCardia's $19M Ch. 11 Sale To Lender Approved
- 3rd Circ. Asked To Reconsider Precedential Jurisdiction Order
- 2nd Circ. On Hunt For Antitrust Theory In $2B Takeda Action
- Apotex Takes Biosimilar Case To Supreme Court
- PharmaCare Stiffly Opposes Customer's Sex Pill Suit
- Health Funds Say Drug Cos. Fixed Skin Cream Prices
- IRS Slams Colo. Dispensary's Refund Bid In Pot Tax Suit
- Evidence Of Copying Is Irrelevant In Hatch-Waxman Cases
- Sen. Leahy On The AIA's 5th Anniversary
- Rep. Smith On The AIA's 5th Anniversary
- IP Fears Keep Life Sciences, Health Care GCs Up At Night
- Device Maker Looks To Nix Fired Worker's Suit Before Trial
- 2nd Circ. To Scrutinize Antitrust Causation In Actos Case
- Pfizer Faces Sanctions Bid In Suit Over Poultry Vaccine
- Deals Rumor Mill: McDonald's, BP, Apollo Global
- Judge Upset 'Entire Balance' Of Biosimilar Law, Amgen Says
- SEC's Spread Bet Argument Fails In Insider Trading Dispute
- Zimmer Knee MDL Shrinks Further Under Judge's Wary Eye
- New Mexico Sues Bristol-Myers For False Marketing Of Plavix
- Drug Cos. Would Have To Justify Price Hikes Under New Bills
- Nature's Way Bashes Ginkgo Pill Suit As Buyers Seek Cert.
- From Fapiao To Gestores: FCPA Risks In China, Latin America
- 3 Steps To Successful Judgment Enforcement
- Monsanto Denied Toss of Herbicide Cancer Lawsuit In Del.
- FDA Panels To Mull Opioid Painkillers In Children
- Fla. Pharmacy Owners To Pay $7.8M To Settle FCA Suit
- Judge Approves Asset Freeze In Roca Labs False Ad Suit
- UN Report On Public Health Access Blasted By Biz Groups
- 3rd Circ. Affirms Toss Of Atty's Fish-Oil Safety Suit
- Bayer's $66B Monsanto Buy To Face Tough Antitrust Scrutiny
- SAC Backs Push For Quinn Emanuel DQ In Elan Investor Suit
- IP Suit Over Amylin Drug Promos Timely, Justices Told
- Takeda Says 2nd Circ. Zanaflex Ruling Torpedoes Actos Row
- Supreme Court Urged To Revive OxyContin Patents
- Valeant Says Investors' Suit Is Based On Hindsight
- Abcodia Pulls Ovarian Cancer Screening Test On FDA Doubts
- Withers Guides Creation Of Trans-Atlantic Stem Cell Venture
- Fed. Circ. Erred On Patent Law Int'l Reach, Justices Told
- The Post-AIA Battleground For Patent Challenges
- Bayer Wins Over Monsanto With $66B Deal
- 3rd Circ. Pens Numerosity Rules In Provigil Antitrust Row
- Actavis Wants False Ad Claims Dismissed With Prejudice
- Gilead Attacks Post-Merger Claim to $50M Cancer Drug Bonus
- Nutraceutical Shakes Some Claims In 'Sugar Pill' Suit
- EU Court Writes Prescription For Pay-For-Delay Enforcement
- 1st Circ. Agrees Chemist's $5.6M Income Is Not Tax-Exempt
- FDA Warning Wire: 'Spore-Forming Bacteria' At Pharmacies
- GlaxoSmithKline Must Fight Paxil Cases In Delaware
- Loeb & Loeb Sees Ex-GC's Employment Suit Revived
- Vanda Wields New Labeling To Stymie Fanapt Generics
- IMS Plans $1.5B Bond To Help Finance $8.9B Quintiles Deal
- Pharma Co. Vendor Sues Over Exec's Departure To Rival
- Boston Scientific Pelvic Mesh Trial Win Overturned
- Deals Rumor Mill: Bayer, Postal Savings Bank Of China, Teneo
- FCA Relator Asks 9th Circ. To Revive Drug Kickbacks Case
- Calif. Says Bad Records Don't Let Taylor-Wharton Dodge Tax
- An End-Run Around Myriad And 'Product Of Nature' Problem
- Should Your Law Firm Move To The Cloud?
- Quinn Emanuel May Face DQ Action In SAC Capital Suit
- Ex-Warner Chilcott Worker Seeks Path To File Age Bias Suit
- Patients Stand By Claims Of Metal Debris In Brains
- Schwarzenegger Supplement Maker Rival Pumps Up Its Case
- Sanofi Kickback Claims Still Lacking, Dismissal Motions Say
- Fed. Circ. Remands Stryker Damages After High Court Ruling
- Nev. Stock Promoter Cops To $33M Pump-And-Dump Scheme
- FDA Concerned About Study On Risks Of Chantix
- Judge Won't Reconsider Globus Securities Suit Dismissal
- Kirby McInerney Named Lead Counsel In NJ Securities Row
- Par Pharmaceutical Says Escobar Nixes Gov't FCA Suit
- Teva Sues United To Enforce Provigil Antitrust Settlement
- Muscle Milk Consumers Seek Cert. In Labeling Suit
- UnitedHealth Cuts Drug, Alcohol Abstention For Hep C Meds
- Taro, Execs Receive DOJ Subpoenas Over Generic Drug Prices
- Quest Diagnostics Wins Appeal On La. Income Tax Refund
- From The Partner's Desk: Paving Your Path To Partnership
- Illumina Wins 'Rare' Early Ban On Rival's Product In IP Row
- Eli Lilly, Canada Fight For Fees In NAFTA IP Policy Row
- Del. Hemispherx Settlement Delayed By CEO's Fla. Case
- 5 Key Takeaways From The GPhA Biosimilars Forum
- Pfizer Didn't Disclose Viagra's Melanoma Risks, MDL Says
- No Proof Ovarian Cancer Screening Tests Work, FDA Warns
- Health Hires: Government Attorneys Join Covington, Foley
- Brand Battles: Dallas Cowboys Go After Youth Football Team
- Humana Overcharges Ill. Patients for HIV Drugs, DHS Told
- 2nd Circ. Backs Clearblue Pregnancy Test False-Ad Ruling
- Woman Convicted In Stolen Medical Device Scheme
- Ferring Gets Extra Exclusivity As Judge Reverses FDA Win
- 3rd Circ. Wellbutrin Case Could Guide Patent Settlements
- Sorrento Therapeutics Investor Says Board Looted Company
- Deals Rumor Mill: Bayer, CenturyLink, Samsung Electronics
- AstraZeneca And The SEC's Focus On Life Sciences
- How We Can Diversify The Legal Profession And Why We Must
- Masimo, Philips Argue For Quick Wins In Blood Sensor Fight
- UCB's Antibody Patent Win Against Yeda Backed By Fed. Circ.
- Euro Drug Pricing's Tradeoffs May Limit Appeal In US
- Boehringer, Teva Want Aggrenox Pay-For-Delay Claims Nixed
- Avexis' $147M Follow-On Offering Leads 2 Biotech Stock Deals
- Neovasc Fights Injunction Request In $70M IP Verdict
- Investor Class Suit Over Cancer Co. IPO Goes To Fed. Court
- Deals Rumor Mill: Bayer, Lone Star Funds, Shop-Apotheke
- Vitamin Health Asks 6th Circ. To Revive Coverage Battle
- Contact Lens Cases Might Bring Clarity To Antitrust Issues
- Feds Drop Case Against Ex-Va. Gov. McDonnell And His Wife
- Intercept's $55M Payout In Stock-Drop MDL Gets Final OK
- Patients Seek Revival Of Diabetes Drug Claims In 9th Circ.
- Buyer Must Give Up Suboxone Docs In Product-Hopping MDL
- Celgene Knocks Feds' Support Of $40B Off-Label FCA Suit
- 1st Circ. Panel Wary Of FCA Suit Against Medtronic Unit
- Johnson & Johnson, Kelly Services Lose FCRA Arbitration Bid
- Vaginal Mesh MDL Judge Sick And Tired Of Bogus Suits
- J&J Hit With More Talcum Powder Ovarian Cancer Claims
- Gilstrap Goof Requires Patent Verdict Fix, Device Co. Says
- Dentsply Urges Mass. High Court To Uphold Fraud Win
- Volcano Investors Appeal 'Radical' Chancery Court Ruling
- J&J Talc Suits Show Evidence Standards Vary Among Courts
- Med Equipment Cos. To Pay $12M To Settle FCA Allegations
- USPTO Fee Rule Upends 170 Years Of History, Fed Circ. Told
- Teva Asks Fed. Circ. To Nix Lilly's Chemo Patent Win
- Depositions Repetitive In Celexa, Lexapro MDL, Forest Says
- St. Jude Sues Over 'Defamatory' Cardiac Device Report
- Sidley Aids PE-Backed Microbiology Co. In Accuratus Lab Buy
- FDA Is Evolving On Qualifications For 'New Chemical Entity'
- Allergan Eye Drop Antitrust Suit Revived By 3rd Circ.
- Leveraging Trial Strategies To Improve Your Negotiating Skills
- Venable Adds Trial-Savvy IP Partner From Orrick
- FDA Warning Wire: Bausch & Lomb, Jazz Pharma, Pan Drugs
- Apotex Cleared Of Amgen Infringement Claims In Fla. Suit
- 3 Potential Claims Mylan Faces In EpiPen Drama
- Nixon Peabody Mistakes Cost Them $8M, Business Trio Says
- SEC Sues Penny Stock CEO Over Promotional Campaigns
- Bull Semen Sorting Row Needs New Trial, Supplier Says
- FTC Says Allergan Must Face Lidoderm Generic Delay Suit
- Danaher Grabs Molecular Diagnostics Co. In $4B Cash Deal
- SEC Rejects Ex-E&Y Partner's Oversight Board Challenge
- Old Skills, New Tricks: Opportunities For Law Librarians
- 1st Circ. Revives Suit Saying CVS Hawked Useless Vitamin E
- Agreement Doesn't Bar Seeger Vioxx Claims, 5th Circ. Hears
- NY To Investigate Mylan's EpiPen School Discounts
- Bayer Sweetens Bid For Monsanto To $127.50 Per Share
- CytRx Shareholders Get Del. Stock-Pump Suit Moving Again
- Mylan Persisted In Delaying EpiPen Generic, Study Says
- Fed. Circ. Erred On Patent Law's Reach Abroad, Justices Told
- Clinton Would Fight Drug Price Hikes With Imports, Fines
- Sanctions Denied As Wal-Mart Supplement False Ad Suit Ends
- Texas High Court Passes On Branch Law's Avandia Fee Fight
- Biotech Co. Escapes Stock Promotion Scheme Class Action
- Alice, Mayo Nix Some TB Test Patent Claims, Keep Others
- Disclose Execution Drug Supplier, 8th Circ. Orders Missouri
- FDA Bans Soap Antibacterial Agents With Potential For Harm
- CardiAQ Says $23M Is Minimum Fair Boost To $70M IP Verdict
- Acclarent Execs Say Their Convictions Violate 1st Amendment
- J&J Beats Pair Of Talcum Powder Ovarian Cancer Suits In NJ
- Alere, Abbott Told To Mull Mediation Before Merger Trial
- Will 'Dr. Bull' Affect Actual Jurors?
- Metal Hip Patient Asks 11th Circ. To Affirm $2M Defect Win
- Pfizer Stockholder Denied Request To Inspect Co. Records
- Pain Therapeutics Gets Nod On $8.5M Remoxy Class Deal
- Allergan OKs Generic Of Alzheimer's Drug Namzaric For 2025
- Feds Give Takeda $20M To Develop, Test Zika Vaccine
- CVS Agrees To Reform Opioid Dispensing Practices In Mass.
- Bayer Shakes Majority Of Essure Twin Pregnancy Suit
- Omnicare Asks To Appeal $421M FCA Suit To 1st Circ.
- Opioid Maker's Investors Say Co. Illegally Marketed Drug
- Senators Want Federal EpiPen Spending Data From CMS
- Foster Pepper, Barack Ferrazzano Steer $134M Seattle Deal